Search results
Results from the WOW.Com Content Network
The top drug, Enhertu, an antibody-drug conjugate (ADC) to treat breast cancer and sold in partnership with pharma company Daiichi Sankyo, recorded sales of $423 million in the US.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Mean peak year sales of drugs discovered by biotechs were $1.22 billion, considerably higher than those discovered by pharmaceuticals at $0.85 billion. ... For example, in a 2006 paper,"Biotech ...
A direct consequence within the pharmaceutical industry value chain is that major pharmaceutical multinationals tend to increasingly outsource risks related to fundamental research, which somewhat reshapes the industry ecosystem with biotechnology companies playing an increasingly important role, and overall strategies being redefined ...
The following is a list of countries by pharmaceutical exports.. Global sales from exported drugs and medicines by country total US$371.3 billion in 2018. Overall the value of drugs and medicine exports grew by an average 5.80% for all exporting countries since 2014 when drugs and medicines shipments were valued at $344.1 billion.
(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
COVID-19 gave a shot in the arm to Pfizer's sales and culture. Now CEO Albert Bourla lays out a plan to replace vaccine revenue as the virus' impact wanes.